serum, 10mMHEPES, 1 mMsodium pyruvate, 5X10"5m 2ME and 100 jUg/ml uridine, to prevent glucose shortage.
Although a number of studies have reported DSGmediated inhibition of immune responses in vitro at concentrations greater than 50~200 //g/ml, we have used MeDSG at concentrations of 5 to 20jUg/ml, which are thought to be achievable in in vivo animal and human pharmacokinetic studies. In our previous studies, when 2-45-12 cells were exposed to 10fig/m\ MeDSG, the cells showed a decline of [3H]-thymidine uptake after 24-hour incubation. Thereafter, the cell viability was gradually reduced and 48 hours later, approximately 60% of the cells underwent cell death via apoptosis5'6). The concentrations of MeDSGused in this study ranged from 0.0025 to 25 jUg/ml, which were lower than those used in our previous studies5'6). Cell growth was evaluated by counting the cell number, using a Coulter Counter model ZM (Coulter Electronics Inc., Beds, U.K.).
As shown in Fig. 1 Eagle's medium containing 4.5 mg/ml of glucose and 10% FCS. On the other hand, p°cells depleted of mtDNAwere grown in the same mediumsupplemented with 100 /ig/ml uridine and 1 mMsodium pyruvate in order to prevent cell death through a decline in intracellular ATP level and to prevent a reduction of pyrimidine biosynthesis by inhibition of the mitochondrial dihydro-orotase dehydogenase complex. When these cell lines were treated with MeDSG,FCS was replaced by horse serum. In our previous studies, MeDSGenhanced mitochondrial reduction of MTTduring apoptosis in growing cells6). Therefore, the effects of MeDSG on cell growth and MTTreduction were examined using cell lines carrying mtDNA(p+) and its derivative lacking mtDNA(p°). Since the osteosarcoma cells and the fibroblast cells were grown slowly, the concentrations of MeDSG used for these cells were higher than those in the experiments of Fig. 1 , and the evaluation was carried out at 120 hours of cultivation. The cell growth was determined as described in the experiments of Fig. 1 , and MTTcolorimertic assay was performed as described previously6^. The results are presented in Fig. 2 T cells (2X 105cells/ml) were plated into 24-well culture clusters and treated with MeDSGin 5% CO2humidified air atmosphere. After 24hours-incubation, the cells were harvested, washed with PBS for 3 times, and suspended in PBS (4X 106cells/ml). The cell suspension was exposed to 3 cycles of rapid freezing/thawing, centrifuged at 10,000 rpm and the supernatant was used as cellular extract. This extract or its culture mediumwas mixed with an equal volume of 0.6m perchloric acid, placed on ice for 10minutes, and then centrifuged. The supernatant was neutralized by the addition of potassium hydroxide, placed on ice for 15minutes, and then filtered. The content of L-lactic acid in the cellular extract or culture medium was measured using a lactic acid assay kit (Boerhinger, Mannheim, Germany)9). were treated with MeDSGfor 24 hours, cell growth was inhibited at the concentrations greater than 0.25/ig/ml MeDSG in a dose-dependent manner. However, cell death was not detected within 24 hours even when treated with 10 /ig/ml MeDSG(data not shown). Fig. 3 shows that MeDSGinduced a significant increase of lactic acid production in the culture mediumof MeDSG-treated p+ cells may be located in mitochondria.
Rotenone, antimycin A or oligomycin inhibits MTT reduction during cell death. Azide that inhibits cytochrome a in mitochondrial complex IV also induces apoptosis, but it also induced a slight enhancement of MTTreduction (Odaka, C, unpublished data). Although, at present, we are not able to define the mechanism by which MeDSGinduces an increase of MTTreduction in growing cells, our findings suggest that MeDSG interferes with the mitochondrial respiratory function in growing cells. Our observations will help to elucidate the mechanism of action of DSG,but further experiments will be necessary to determine how DSGinterferes with particular molecule(s) in the complex of mitochondrial respiratory chain.
